

Table SI. Mean annual direct and indirect costs of patients with psoriasis, in 2006 inflation-adjusted with consumer price index to 2009 price level and in 2009

Treatment group	<i>n</i>	Biologics SEK ^a	Conventional agents SEK ^a	Topical agents SEK ^a	Outpatient health care SEK ^a	Inpatient health care SEK ^a	Total mean direct costs SEK ^a	Sick leave SEK ^a	Disability pension SEK ^a	Total mean indirect costs SEK ^a
2006, <i>n</i> =52,135										
Biologically	1,233	106,081	1,175	2,411***	4,941***	4,282***	118,891*	46,446***	77,496*	123,943***
Non-biologically	7,196	–	1,736	1,987***	3,235***	2,532***	9,450***	23,092***	41,502***	64,594***
Topically	43,706	–	–	1,926***	906***	224***	3,055***	7,156***	16,386*	23,541***
All patients		2,509***	267***	1,946***	1,323***	638***	6,683***	10,285***	21,298*	31,582***
2009, <i>n</i> =59,720										
Biologically	2,227	106,313	1,119	1,731	4,072	1,835	115,070	24,260	66,058	90,319
Non-biologically	9,153	–	1,712	1,639	3,021	838	7,211	14,013	34,405	48,418
Topically	48,340	–	–	1,727	1,008	104	2,838	5,322	14,819	20,141
All patients		3,964	304	1,714	1,430	281	7,694	7,360	19,732	27,092

Statistically significant differences between years were indicated at *p*-values * <0.1 **<0.05 *** <0.001.

^a1 Euro ~ 9 SEK (2014)